Table 1.
Demographic and clinical features of 126 MOG-IgG1-positive Sri Lankan patients
| Characteristics | MOG-IgG1-positive patients, N (%) | ||
| Total N=126* | Paediatric N=44† | Adult N=82† | |
| Age at onset, years, median (range) | 26 (3–68) | 9 (3–18) | 33.5 (19–68) |
| Sex, female | 70 (56) | 22 (50) | 48 (58) |
| Symptoms at onset | |||
| Optic neuritis (alone) | 64 (51) | 17 (39) | 47 (57) |
| Transverse myelitis | 29 (23) | 7 (16) | 22 (28) |
| ADEM | 11 (9) | 11 (25) | 0 (0) |
| Optic neuritis and transverse myelitis | 8 (6) | 2 (4) | 6 (7) |
| Optic neuritis and ADEM | 13 (10) | 7 (16) | 6 (7) |
| Optic neuritis and intractable hiccups | 1 (1) | 0 (0) | 1 (1) |
| Clinical phenotype at last follow-up | |||
| Optic neuritis (single or relapsing) | 58 (46) | 16 (36) | 42 (52) |
| Transverse myelitis | 24 (19) | 4 (10) | 20 (24) |
| ADEM | 12 (10) | 12 (27) | 0 (0) |
| NMOSD | 32 (25) | 12 (27) | 20 (24) |
| Duration of follow-up, years, median (range) | 4 (0.12–20) | 3 (0.5–18) | 3 (0.25–20) |
| Number of patients with relapsing course | 43 (34) | 15 (34) | 28 (34) |
| Median number of relapse (range) | 1 (1–9) | 1 (1–8) | 1 (1–9) |
| Acute treatments‡ | 115 (100) | 44 (100) | 82 (100) |
| Long-term immunotherapy§ | 55 (50) | 18 (45) | 38 (53) |
The final diagnoses for the 355 MOG-IgG1 seronegative adult cases were in decreasing order of frequency: optic neuritis (133), transverse myelitis (76), MS (45), AQP4-IgG-positive NMOSD (24), CRION (12), ADEM (4) and other (61).
*Available MRI spine data were available for 33 patients, who presented with transverse myelitis alone and optic neuritis with transverse myelitis. A total of 14 of the 126 patients were initially diagnosed as MS but subsequently tested positive for MOG-IgG.
†Clinical data were available for 550 patients: The final diagnoses for the 69 MOG-IgG1 seronegative paediatric cases were in decreasing order of frequency: transverse myelitis (24), optic neuritis (17), ADEM (8), MS (6), AQP4-IgG-positive NMOSD (4) CRION (1) and other (9).
‡Acute treatments included intravenous methylprednisolone, plasma exchange, immunoglobulin G and combination (data available for 115 patients).
§Long-term immunotherapy included azathioprine, prednisolone, mycophenolate mofetil and combination (data available for 110 patients).
ADEM, acute disseminated encephalomyelitis; CRION, chronic relapsing inflammatory optic neuropathy; MOG, myelin oligodendrocyte glycoprotein; MS, multiple sclerosis; NMOSD, neuromyelitis optica spectrum disorders.